NeuroSearch A/S is a Danish biotechnology company specializing in pharmaceuticals for treating diseases and disorders affecting the central nervous system (CNS).
NeuroSearch was founded in Denmark in April 1989 as one of the first companies in the Medicon Valley area around Copenhagen and Malmö, with 25 employees and €4,000,000 in private financing.
Its Danish founders included femoxetine and paroxetine inventor Jørgen Buus Lassen and Asger Aamund (da).
The investigators concluded that tesofensine could produce at least twice the weight loss of currently approved anti-obesity drugs and should be evaluated in phase 3 trials.
The company sold its rights to its lead product candidate, Pridopidine for the treatment of patients with Huntington's disease to Teva Pharmaceutical Industries.